TLR4 and neoplasm: The specific TLR4 inhibitor, CLI‐095, inhibits rapid fetuin‐A uptake, and consequently, most tumor cells, particularly those that do not synthesize fetuin‐A, fail to adhere, spread, or grow in serum‐free medium.